MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s10072-019-04220-8

Медицинская библиотека · Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2020

Vitamin D3 might improve headache characteristics and protect against inflammation in migraine: a randomized clinical trial.

Ghorbani Zeinab, Togha Mansoureh, Rafiee Pegah, Ahmadi Zeynab Sadat, Rasekh Magham Reyhaneh, Djalali Mahmoud, Shahemi Sahar, Martami Fahimeh, Zareei Mahnaz, Razeghi Jahromi Soodeh, Ariyanfar Shadi, Mahmoudi Maryam

СтатьяРандомизированное исследованиеПеревод в очереди

Аннотация

INTRODUCTION

Due to anti-inflammatory effects of vitamin D3, we aimed to explore the effects of supplementation with this vitamin on headache characteristics and serum levels of pro/anti-inflammatory markers in migraineurs.

METHODS AND MATERIALS: This placebo-controlled, double-blind study included 80 episodic migraineurs who randomly assigned into two equal groups to receive either daily dose of vitamin D3 2000 IU (50 μg) or placebo for 12 weeks. At baseline and after the trial, headache characteristics were determined using diaries and serum levels of interleukin (IL)-10, IL-6, inducible nitric oxide synthase (iNOS), and cyclooxygenase-2 (Cox-2) were assessed via ELISA method.

RESULTS

At the end of trial, analysis of covariance (ANCOVA) adjusted for baseline values, and confounders revealed that vitamin D3 supplemented group experienced significantly lower headache days per month (4.71), reduced attacks duration (12.99 h/attack), less severe headaches (5.47, visual analog scale), and lower analgesics use/month (2.85) than placebo group (6.43, 18.32, 6.38 and 4.87, respectively) (P values < 0.05). Using ANCOVA adjusted for baseline levels and confounding variables, it was found that serum levels of IL-10 and Cox-2 did not significantly differ between groups after the experiment; whereas, iNOS serum level was significantly reduced in the intervention group (106.06 U/L) comparing to the controls (156.18 U/L P : 0.001). Also, the patients receiving vitamin D3 yielded a marginally significant lower IL-6 serum concentration (76.43 ng/L) compared to placebo (93.10 ng/L) (P value:0.055).

CONCLUSION

Based on the results of this study, we found that 2000 IU (50 μg)/day vitamin D3 supplementation for 12 weeks could improve headache characteristics and might reduce neuro-inflammation in episodic migraine.

Для цитирования: Ghorbani Zeinab, Togha Mansoureh, Rafiee Pegah, Ahmadi Zeynab Sadat, Rasekh Magham Reyhaneh, Djalali Mahmoud, Shahemi Sahar, Martami Fahimeh, Zareei Mahnaz, Razeghi Jahromi Soodeh, Ariyanfar Shadi, Mahmoudi Maryam. Vitamin D3 might improve headache characteristics and protect against inflammation in migraine: a randomized clinical trial.. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 2020. DOI: 10.1007/s10072-019-04220-8.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.